Is hearing impairment associated with HIV? A systematic review of data from low- and middle-income countries. by Ensink, Robbert JH & Kuper, Hannah
Ensink, RJH; Kuper, H (2017) Is hearing impairment associated with
HIV? A systematic review of data from low and middle-income coun-
tries. Tropical medicine & international health. ISSN 1360-2276 DOI:
https://doi.org/10.1111/tmi.12993
Downloaded from: http://researchonline.lshtm.ac.uk/4609927/
DOI: 10.1111/tmi.12993
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/tmi.12993 
This article is protected by copyright. All rights reserved. 
Article Type: Original Article 
 
Is hearing impairment associated with HIV? A systematic review of data from low and middle-
income countries 
 
Robbert JH Ensink1 and Hannah Kuper2  
1 Gelre Hospital, Zutphen, The Netherlands 
2 International Centre for Evidence in Disability, London School of Hygiene & Tropical Medicine, UK 
 
Abstract 
Objectives: To systematically review evidence on the prevalence and characteristics of hearing 
impairment among children and adults living with HIV in low and middle-income countries (LMIC). 
Methods: Articles were identified up to January 2016 through searching four electronic databases. 
Epidemiological studies conducted in LMIC that explored the association between HIV status and 
hearing loss, with or without an HIV-uninfected comparison group, were eligible for inclusion. 
Results were screened and assessed for eligibility and data were extracted by two reviewers, with 
discussion in the case of disagreement. Findings were narratively synthesized. 
Results: The search identified 638 unique references, of which 21 studies were included in the 
review, including 3491 people with HIV from 13 LMIC. There was lack of consistency in the definition 
used for hearing loss, making comparability across studies difficult. Among children with HIV, across 
the three studies that used a cut-off of >15dB in either ear, the prevalence of hearing loss ranged 
from 22-37%. Among the three studies that used >25dB in either ear, the prevalence ranged from 
32-39%. Among adults with HIV, for the five studies that used a threshold of >25dB for either ear, 
the prevalence ranged from 10-43%. The prevalence of hearing impairment was significantly higher 
among people with HIV than in controls in eight of the ten studies that assessed this comparison. 
Conductive hearing loss was the most common type of hearing loss in children with HIV, while 
sensorineural hearing loss was more common in adults with HIV. There was a lack of evidence for an 
association between ART use and hearing loss, though there was some suggestion that late stage of 
HIV disease or low CD4 count was related to hearing loss. There were concerns about the quality of 
the studies included in the review. 
Conclusions: The current evidence is suggestive of a high prevalence of hearing loss among people 
living with HIV compared to people without HIV, or to WHO estimates for the general population. 
More research is needed to better understand the aetiology of hearing loss in relation to HIV, and 
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whether screening for and treatment of hearing loss can be effectively integrated into HIV treatment 
services needs further research.  
 
Keywords: Hearing impairment, HIV, screening, epidemiology, low and middle-income countries, 
systematic review 
 
Introduction 
Sub-Saharan Africa contains 70% of the worldwide 35.3 million people living with HIV.[1] Access to 
anti-retroviral therapy (ART) has become widely available even in these countries in the last 
decade.[2] Consequently, life expectancy of people living with HIV has increased dramatically, and 
HIV is fast becoming more of a chronic illness.[3] Evidence is growing that with increased life 
expectancy there is an emergence of long-term consequences of HIV.[4] The focus of HIV 
programmes must therefore shift from saving life to improving the quality of life of people living 
with HIV.  
One of the potential long-term consequences of HIV is on hearing impairment. In high-income 
countries, up to 75% of adults infected with HIV experience various oto-rhino-laryngological 
symptoms during the course of their disease, including hearing loss.[5] Hearing loss is gradual in 
most cases, but may be sudden in nature in others.[6] Studies in high-income countries in adults 
show that sensorineural hearing loss (SNHL) presents in about one-third of all adult individuals 
infected with HIV, and this can occur as a result of opportunistic central nervous system infections 
causing meningitis or encephalitis (e.g. toxoplasmosis, syphilis, herpes and CMV) or by the HIV virus 
itself. [6,7,8,9] Other sensorineural causes can be iatrogenic in nature, for instance, as a result of 
ototoxic drugs administered for co-infections such as TB, or ARTs.[10] SNHL in HIV is irreversible and 
so a focus should be on its prevention. Children infected with HIV are also at risk of hearing loss, and 
studies from the US estimate that about 20% of HIV-positive children have hearing loss.[6] Hearing 
loss in these children appears to be mainly conductive (i.e. located in the middle ear), probably 
because the immune-compromised child is at a higher risk of developing otitis media and chronic 
suppurative otitis media. [11] This means that hearing loss in children with HIV should mostly be 
treatable, given availability of services.[12]   
Assessing hearing function in people living with HIV is therefore potentially important, since 
good hearing is important for social participation, and inclusion in employment and education. 
However in most low and middle-income countries (LMIC) access to oto-rhino-laryngological care is 
limited, ENT doctors are rare and often only available in the capital city.[12] Furthermore, screening 
programmes are virtually non-existent and access to hearing aids is very rare. Careful consideration 
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is therefore needed of the prevalence and cause of hearing loss among people living with HIV, in 
order to show how best to provide prevention and treatment services to mitigate hearing loss in 
LMICs.  
The objective of this study was to systematically review evidence on the prevalence and 
characteristics of hearing loss among children and adults living with HIV in LMIC, in order to inform 
HIV programm planning in these settings.  
 
Methods 
The systematic review was planned, conducted and reported according to established PRISMA 
guidelines [13] A systematic literature search was conducted in January 2016 for peer-reviewed 
articles that presented original research findings on hearing loss among people with HIV in LMICs. A 
specific review protocol was not published separately. 
 
Search strategy 
Four electronic databases, PubMed, Web of Science, EMBASE, and Global Health, were searched in 
January 2016. Search terms for HIV/AIDS and hearing impairment were identified through MeSH as 
well as from those used for systematic reviews on similar topics. The date of publication was 
restricted from 1980 to January 2016 as HIV/AIDS was recognised in the early 1980s. Furthermore, 
the reference lists of all included papers were screened to identify further eligible papers.  
Articles were screened by two reviewers (RE and HK), first by titles, then by abstract and finally 
by full text to determine eligibility in the final sample. There was discussion until consensus was 
reached in the event of disagreement. The search strategy is presented in Figure 1. 
 
Study selection 
Studies were eligible if they met the following criteria: (1) Original research that included HIV and 
hearing impairment, (2) results reported or allowed calculation of prevalence of hearing impairment 
among people with HIV, (3) all people in the sample were screened for hearing impairment, and (4) 
conducted in an LMIC as defined by the World Bank country classification 2015.  
 
Both HIV status and hearing impairment could be assessed through self-report, clinical 
assessment or medical records. Any study with an epidemiological design was eligible for inclusion 
(survey, case-control, cohort, trials). Given the expectation that there would be a dearth of 
information, studies with and without comparison groups were included.  
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Exclusion criteria comprised: (1) full text unavailable, (2) duplicate reports from the same study, 
(3) studies that investigated hearing impairment as a risk factor for HIV infection, (4) qualitative 
studies, (5) case reports (i.e. sample size <10), and (6) study population comprised patients with HIV 
presumed to be at high risk for hearing loss (e.g. those attending ENT services, those with multi-drug 
resistant TB).  
 
Data extraction and analysis 
The following data were extracted from articles that met the inclusion criteria: General study 
information (title, author, year of publication), study design, study setting and dates conducted, and 
population characteristics. The primary research outcomes extracted were: prevalence of hearing 
impairment among people with HIV, and odds ratio for the relationship between hearing 
impairment and HIV if a comparison group was available. Furthermore, odds ratio for the 
relationship between measures of HIV disease status (CD4 count or WHO stage) and hearing 
impairment were recorded. All these estimates were calculated from available data when they were 
not presented in the paper. 
 
All data were extracted by the two authors and compared for any differences, which were 
discussed so that a consensus was reached. 
 
Meta-analysis was not used to pool results, due to the lack of standardised measures of hearing 
loss and heterogeneity in study designs and consequently a narrative approach was taken. Studies 
using a comparison group were described separately from those without.  
 
Quality assessment 
Quality assessment of the eligible studies was conducted using a modified version of the quality 
assessment tool for systematic reviews of observational studies (QATSO). Criteria included the 
following: (1) two measures on representativeness of the sampling method (use of probability 
sampling to select study participants, population-based recruitment), (2) objectivity of measurement 
of HIV, (3) validated hearing impairment measurement, (4) acceptable response rate (60% of higher) 
and (5) control for confounding in studies with a comparison group.  
 
Results 
The search identified 638 unique references, after removal of duplicates. Of these, 435 records were 
excluded after screening titles, and a further 162 records after screening abstracts. 41 papers were 
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identified for full text review. Twenty-two studies were not eligible, because they did not include a 
measure of hearing loss (n=10) or HIV (n=3), were conducted in a high income setting (n=2), were an 
ineligible research design (n=4, e.g. reviews or included an ineligible group of HIV participants such 
as people with HIV and MDRTB), were not in English (n=1)[14] or the full text could not be retrieved 
(n=2). [15,16] Two further eligible studies were identified through screening references of eligible 
papers [20,27] Finally, 21 eligible articles were included in the review. These 21 studies included 
3491 people with HIV in 13 LMIC settings. 
The characteristics of the eligible studies are summarised in Table 1.[17-37] Eleven studies 
focused on children, nine on adults, and one on people of all ages. Eleven of the studies included 
both cases with HIV and HIV uninfected controls, while the remaining ten included only patients with 
HIV. The majority of the studies were conducted in sub-Saharan Africa (n=13), with the remainder 
undertaken in Latin America (n=6) or India (n=2). Almost all of the studies were carried out in clinical 
settings. None of the studies included self-reported HIV status; in all HIV status was clinically 
verified. None of the studies used probability sampling, and none reported the response rate. 
Hearing was assessed clinically in twenty studies; only one study assessed hearing impairment 
through self-report and none extracted the data from medical records. 
Most of the studies included in the review used pure tone audiometry (PTA) to measure hearing 
loss, but a range of different cut-offs was used for hearing loss, particularly among the children. 
(Table 2) There was also a lack of consistency as to whether hearing loss was determined on the 
basis of either ear or in the better ear. Among children with HIV, the prevalence of hearing loss 
varied from 4% to 85% overall. Across the three studies that used a cut-off of >15dB in either ear, 
the prevalence of hearing loss among children with HIV ranged from 22-37%. Among the three 
studies that used >25dB in either ear (or did not state whether it was for either ear), the prevalence 
ranged from 32-39%. Among adults the prevalence of hearing loss ranged from 10%-68%. Among 
adults, a threshold of >25dB was used more consistently to determine hearing impairment. There 
were five studies that used this threshold for either ear (or did not state whether it was for either 
ear), and the prevalence ranged from 10-43%. The prevalence of hearing impairment was 
consistently higher among people with HIV than in controls. Among children, four of the five studies 
that compared children with and without HIV found a significant association between HIV and 
hearing loss (Figure 2). Similarly, among adults, four of the five studies that included cases and 
controls found a significantly higher odds of hearing loss among people with HIV compared to 
uninfected controls. These comparisons were mostly unadjusted.  
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A variety of examination methods were used to identify the type of hearing loss (Table 3). 
Among the seven studies that explored cause of hearing loss in children, four found that conductive 
hearing loss was the most common type. In contrast, among the seven studies that assessed cause 
of hearing loss in adults, five found that SNHL was the most common type of hearing loss. Nine 
studies articles reported in detail on otoscopy findings.[19,21,25,29-33,37] Chronic suppurative otitis 
media (CSOM) prevalence varied from 16 to 36% in children and adults with HIV. Two studies 
reported on the prevalence of eardrum perforations in children, and reported these as 9% [19], and 
10% [23] respectively. One article reported prevalence of perforations in adults of 8%. [33] Two 
articles reported on a prevalence of acute otitis media with effusion (A)OME respectively of 5% [21] 
and 10% [19], respectively. 
Fourteen studies investigated the relationship between clinical features of HIV and hearing loss 
(Table 4). Ten studies reported on relationship between ART and hearing loss, of which three found 
evidence of an association, although for one this was restricted to a sub-group. [7] In contrast, three 
of the five studies that investigated the relationship between low CD4 count and hearing loss found 
a positive association. Similarly, there was consistent evidence for an association between stage of 
HIV and hearing loss. There was less evidence of a relationship of hearing loss with low viral load or 
opportunistic infections.  
The quality assessment highlighted several concerns about the studies included in the review 
(Table 5). None of the studies were population based or used probability sampling, and the response 
rate was consistently not reported. Furthermore, only one study controlled for confounding in the 
primary analyses of the relationship between HIV and hearing impairment. In terms of strengths, all 
studies included objective measures of HIV assessment, and all but one used validated assessment 
tools to determine the presence of hearing impairment. 
 
Discussion 
This systematic review summarizes evidence from 21 studies of hearing impairment prevalence 
among 3491 people with HIV in 13 LMIC settings. To our knowledge, this is the first systematic 
review of hearing loss among people with HIV. There was a high degree of variability in estimates, 
attributable at least in part due to the lack of consistency in thresholds used to define hearing loss or 
methods used to measure hearing loss. Overall, however, approximately one in three people living 
with HIV appear to experience a hearing impairment. These figures are greater than the estimates 
for the general population provided by WHO that suggest that 15% of the world’s adults population 
has some degree of hearing loss (>25 dBHL in better ear) of whom one third have disabling hearing 
loss (>40 dBHL) [38]. In particular, the level of hearing impairment in children with HIV far exceeds 
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the estimates from WHO of approximately 1.4% have disabling hearing loss (>35 dBHL).[39] 
Furthermore, in 8 of 10 studies that compared cases with HIV to HIV-uninfected controls there was a 
statistically significant association between HIV and hearing loss, and this was apparent in both 
adults and children. These estimates are in line with those from high income countries, indicating 
that hearing loss is relatively common among people living with HIV. [6,40] 
Several of the studies investigated the cause of hearing loss, among people with HIV, as well as 
the presence of other ear conditions. There was a great variation in methods used here also, 
including whether tympanometry, air/bone audiometry, otoscopy and/or other examinations were 
undertaken. Only 9 of 21 articles included reported their otoscopy results in detail. When middle ear 
dysfunction is not properly investigated a higher proportion of SNHL will be found. This implies that 
the percentage of treatable causes of hearing loss might be even higher than calculated in this 
review. However, there were clear patterns in cause; among children hearing loss was most 
commonly a conductive hearing loss, while in adults this was more likely to be SNHL. These findings 
are consistent with those studies from high-income countries. [41,42,43] In children, the conductive 
hearing loss is likely to result from frequent ear infections; several studies reported frequent CSOM 
among the children with HIV.[19,21, 25, 26, 29-32,37] Although the study samples were generally 
small, these CSOM prevalences were similar to the otoscopical abnormalities found in 14-37% of 
ears in high-income countries. [6,43] Overall, 8-10% of children with HIV had an eardrum 
perforation. These estimates are far higher than would be expected from the general population. For 
instance, the largest study in Africa on 5368 schoolchildren (not tested for HIV) showed a prevalence 
of eardrum perforations of only 2.4% with 1.1% of children having a CSOM. [44]  
The high prevalence of hearing loss and ear conditions among people living with HIV reported in 
this review is consistent with previous studies. For instance, a study from Ivory Coast in children 
showed that non-specified ENT-manifestations in HIV accounted for one third of HIV related 
presenting symptoms. [45] Similarly in a study among South Africa children CSOM was often a 
presenting symptom of HIV in 54% of investigated children under the age of 6 years. [46] In 
Cameroon approximately 12% of patients discovered their HIV status after an oto-laryngological 
event. [47]  
There was some evidence for a relationship between hearing loss and specific characteristics of 
HIV disease, in particular, signs of advanced disease, though data were lacking and not always 
consistent. Three of five studies that investigated the relationship between a low CD4 count and 
hearing loss found a positive association. The association between ART and hearing loss was less 
clear. It is likely, however, that ART therapy would prevent the discharging periods of acute otitis 
media, resulting in a lower prevalence of CSOM, and consequently less hearing loss in children. On 
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the other hand, ART may be given to people with more advanced disease, which may be 
independently related to hearing loss, thus concealing the potentially positive impact of ART on 
preserving hearing. There is also the possibility that ART itself may cause hearing loss, through 
ototoxicity.  
The majority of the studies used PTA or ABR to determine hearing loss, and only one study used 
self-report measures. There was no specific audiological pattern found among HIV patients. A recent 
study reports on a marked low tone perceptive hearing loss however only described in adult patients 
[40] and in one study unilateral hearing loss, with a difference of > 20 dB was reported in 40% in an 
American population and in 20% in South African children. [42,43] Chandreskar and Makau found 
higher levels of hearing impairment at 4 and 8 kHz among people with HIV, however in these studies 
many patients were on ART treatment.[6,29] In another study in individuals on ART treatment, high 
tone hearing loss was absent and but affected more frequencies.[31] In one study where patients 
were not on ART treatment, a similar high tone hearing loss was described.[30] Various explanations 
are possible for these high frequency hearing losses; not only HIV itself but also co-existing 
neurotropic infections such as CMV, herpes; ototoxic drugs for co-existing TB, or ototoxic 
aminoglycoside drops used in open middle ears can account for these hearing losses. One study was 
identified that undertook hearing screening by oto-acoustic emissions (OAE) alone, but was not 
included in this review as the target group was HIV-exposed children, rather than HIV-positive 
children.[48] Although no statistically significance was found, in 11,1% of neonates a hearing loss 
over 20 dB was found and correlated with a CD4 % lower than 25 in the neonate. More recent 
studies report on specific audiological findings by OAE screening, however their results provide so 
far no adequate tools to implement in screening programs for hearing loss in the younger children 
with HIV. [27,34] 
Overall, this review showed strong evidence supporting a relationship between HIV and hearing 
loss. Consequently, there is clear justification for routinely screening children and adults living with 
HIV for hearing loss and other ENT symptoms. Self-report of hearing loss is likely to be insufficient, 
since the onset of hearing loss is usually slow. OAE screening is likely to be inappropriate for sub-
Saharan African setting, given low access to these screening facilities, as well as lower detection 
rates of severe hearing losses. [49] Clinical screening using audiology is therefore recommended, as 
often happens in high income settings. This screening is now more feasible with the availability of 
low cost mobile tools, such as HearTest and HearScreen.[50] An ear examination would also be 
helpful to identify other ear conditions, such as CSOM, although constraints on the availability of 
skilled staff may make this difficult to implement.  
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Protocols will need to be developed and field-tested in order to determine which mode of 
screening for hearing impairment among people with HIV is most cost-effective in a resource 
constrained setting. Furthermore, future studies should use standard means for measuring and 
defining hearing loss, ideally in line with the WHO categories. Greater standardization in the 
examination of ears, to determine cause of hearing loss, would also be helpful. More evidence is 
needed on the causes of hearing loss among adults and children with HIV, so that interventions can 
be developed and tested. The repeated screening for hearing loss within longitudinal studies of 
people living with HIV will help to improve our understanding of the aetiology of hearing loss 
associated with HIV.  
There are important strengths to this review. It was the first systematic review on this topic, and 
included studies from low and middle-income countries, across children and adults. There are also 
limitations. There was a high degree of variability in how hearing loss was categorised, and concerns 
about the quality of the data. The studies did not routinely investigate the aetiology of the hearing 
loss, and so there was potential for bias in reporting of associations between hearing loss and 
characteristics of HIV. All of the studies were carried out in clinical settings, and so evidence is not 
available about the prevalence of hearing loss among people with HIV who are not aware of their 
status and/or not being medically managed. The review was restricted to papers published in 
English, although in reality this led to the exclusion of only one article.[14] Furthermore, uptake and 
use of ENT services was not assessed, but is likely to have been low. 
In conclusion, the evidence is suggestive of a high prevalence of hearing loss among people 
living with HIV. More research is needed to consider the aetiology of hearing loss in relation to HIV, 
and whether screening for and treatment of hearing loss can effectively be integrated into HIV 
treatment services in low and middle-income settings.  
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Figure 1 Search strategy with flow diagram 
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Figure 2: Odds of the association between hearing loss and HIV, among adults and children 
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Table 1: Description of studies included in review 
Author, 
year 
Country Study 
design 
Clinic or 
population 
sample 
Population PLHIV 
(n)  
HIV – 
controls 
(n) 
Age 
range 
(years) 
Mean 
age 
(years) 
% 
female 
Child sample         
Matas,  
2006 [17] 
Brazil Case-
control 
Population Children 51 50 3-10 - 50% 
Palacios, 
2008 [18] 
Mexico Survey Clinic Children 23 - 0-17 4.5 48% 
Taipale, 
2010 [19] 
Angola Case-
control 
Clinic Children 78 78 0.75-
14.8 
5.4 54% 
Buriti, 2012 
[20] 
Brazil Survey Clinic Children 23 - 2-10 5.7 56% 
Chao,  
2012 [21] 
Peru Survey Clinic Children 139 - 4-19 9.9 52% 
Makar, 
2012 [22] 
India Survey Not stated Children 67 - 4-16 11.1 42% 
Ndoleriire, 
2012 [23] 
Uganda Survey Clinic Children  370 - 0.5-5 3.0 47% 
Devendra, 
2013 [24] 
Malawi Case-
control  
Clinic Children 296 296 2-9 5.9 50% 
Matsekete, 
2014 [25] 
Zimbabwe Survey Clinic Children 380 - 5-17 11 55% 
Torre,  
2015 [26] 
South 
Africa 
Case-
control 
Clinic Children 37 24 4-14 7.1 51% 
Maro,  
2016 [27] 
Tanzania Case-
control 
Clinic Children 131 113 <18 10.1 49% 
          
All ages          
Matas, 
2010[28] 
Brazil Case-
control  
Population 51 
children, 
50 
children, 
75  3-10.1  
 
- 
 
Children: 
57% 
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22 adults 25 
adults 
18-50 - Adults: 
36% 
          
Adults          
Makau, 
2010 [29] 
Kenya Case-
control 
Clinic Adults 544 - 18-50 - - 
Ongulo, 
2010 [30] 
Kenya Case-
control 
Clinic Adults 194 124 18-50 35 61% 
Khoza 
Shangase, 
2011 [31] 
South 
Africa 
Survey Clinic Adults 150 - 20-46 33.9 65% 
Suleyman, 
2011 [32] 
Nigeria Survey Clinic Adults 89 - 18-56 36.4 47% 
Westhuizen, 
2012 [33] 
South 
Africa 
Case-
control 
Clinic Adults 200 184 18-60 37 44% 
(cases) 
Maro, 
 2014 [34] 
Tanzania Case-
control 
Clinic Adults 449 202 >18 39 64% 
Matas, 
 2014 [35] 
Brazil Case-
control 
Clinic Adults 45 30 20-60 40 49% 
Mathews, 
2014 [36] 
India Survey Clinic Not stated 60 30 Not 
stated 
Not 
stated 
Not 
stated 
Fokouo, 
2015 [37] 
Cameroon Case-
control 
Clinic Adults 90 90 15-49 33 72% 
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Table 2: Prevalence of hearing impairment in relation to HIV  
Author, 
year 
Measure of 
hearing 
Cut-off for 
hearing 
loss 
Either ear 
or best ear 
Prevalence 
of hearing 
loss 
PLHIV 
Prevalence 
of hearing 
loss HIV- 
controls 
Unadjusted OR Age- sex 
adjusted OR 
Child        
Matas,  
2006 [17] 
PTA, ABR,  >15dB for 
ABR and 
PTA 
Either ear 37% Not 
available 
- - 
Palacios, 
2008 [18] 
ABR (all ages) 
PTA (aged 4+) 
>20dB for 
PTA and 
ABR 
 
 
Not stated 26% for 
ABR  
33% for 
PTA 
- - - 
Matas,  
2010 [28] 
PTA >15dB Either ear 28% 0% NA  
Taipale,  
2010 [19] 
BERA (all ages) 
PTA (aged 5+) 
>60 dB 
(BERA) 
 
All ears 
and better 
ear 
All ears: 
8% 
 
Better ear: 
4% 
All ears: 
3% 
 
Better ear: 
0%  
All ears: 3.0 (1.0-9.7)* 
 
Better ear: NA 
 
  >25 dB 
(PTA) 
All ears 
and better 
ear 
All ears: 
33% 
 
Better ear: 
23% 
All ears: 
15% 
 
Better ear: 
3% 
All ears: 2.4 (1.0-5.9)* 
 
Better ear: 9.5 (1.1-83.3)* 
 
Buriti, 
 2012 [20] 
PTA >15dBHL Either ear 85% of 
ears 
 
- -  
Chao,  
2012 [21] 
PTA >25dB  Either ear 39% - -  
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Makar,  
2012 [22] 
PTA Not stated Not stated 33% - -  
Ndoleriire, 
2012 [23] 
ABR, 
Tympanometry 
>25dB 
ABR 
Not stated 33% - -  
Devendra,  
2013 [24] 
Self-report Difficulty 
hearing 
Either ear 12% 2% 5.7 (2.5-13.1)* 6.2 (2.7-14.3) 
Matsekete,  
2014 [25] 
PTA >25 dB 
>40 
>60 
Not stated 32% 
11% 
3% 
- -  
Torre,  
2015 [26]  
OAE, PTA,  >15dB Either ear 22% 8% 3.0 (0.6-15.7)*  
Maro,  
2016 [27] 
OAE,PTA >25 dB Better ear 12% 5% 3.0 (1.0-8.5)*  
        
Adults        
Matas, 
 2010 [28] 
PTA, ABR, 
Tympanometry 
>25dB Not stated 41% 0% NA  
Makau,  
2010 [29] 
PTA, tuning fork >25dB  Not stated 31% - -  
        
Ongulo,  
2010 [30] 
PTA >25dB Not stated 34% 8% 5.7 (2.8-11.7)  
Khoza 
Shangase, 
2011 [31] 
PTA >25dB Either ear 10% - -  
Suleyman, 
 2011 [32] 
PTA Not stated  68%    
Westhuizen, 
 2012 [33] 
PTA, OAE, 
tympanometry 
>25 dBHL  Either ear 
and better 
ear 
Either ear: 
43% 
 
Better ear: 
26% 
Either ear: 
6% 
 
Better ear: 
2.5% 
Either ear: 11.9 (6.1-23.2)* 
 
Better ear: 12.6 (4.9-32.0)*  
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Maro,  
2014 [34] 
PTA, ABR >40 dB HL Better ear 3.1% 3.5% 0.9 (0.2-3.5)*  
Matas,  
2014 [35] 
ABR >20 dB  Average 
across ears 
40% 0% -  
Mathews, 
 2014 [36] 
PTA Not stated Not stated 53% 13% 7.4 (2.3-23.9)*  
Fokouo,  
2015 [37] 
PTA (air/bone) >20dB Either 
ear** 
27% 6% 
 
6.2 (2.2-17.1)*  
 
* Calculated from figures in paper 
**Estimate of proportion of ears with hearing loss 
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Table 3: Type of hearing loss among people living with HIV 
Author, year Examination Conductive HL SNHL Mixed 
 
Children 
 
    
Palacios,  
2008 [18] 
PTA, ABR, 
vestibular 
assessment 
50% (children>4) 
75% (children<4) 
  
Chao,  
2012 [21] 
PTA, 
Tympanometry, 
Otoscopy 
89% 2% 9% 
Makar, 2012 [22] Not stated 33% 45% 55% 
Ndoleriire, 2012 [23] ABR, 
Tympanometry 
36% 64%  
Torre,  
2015 [26] 
dpOAE, 
Tympanometry, 
PTA,  
63% 38%  
Matas, 
 2010 [28] 
PTA, 
Tympanometry,ABR  
25% 
 
2% 0% 
 
Adults 
 
    
Matas 
2010 [28] 
PTA, tympanometry, 
ABR  
14% 18% 9% 
Makau,  
2010 [29] 
PTA, tuning fork, 
Otoscopy 
 Most common Least common 
Ongulo, 
 2010[30] 
Otoscopy, PTA, 
tuning fork 
22% 74% 4% 
Khoza Shangase, 
2011[31] 
Otoscopy, PTA, 
Tympanometry 
73% 27%  
Suleyman, 2011 [32] PTA, Otoscopy 32% 14% 52% 
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Westhuizen 
2012 [33] 
PTA, Otoscopy, 
dpOAE, 
Tympanometry 
29% 64% 7% 
Matas,  
2014 [34] 
PTA, 
Tympanometry 
28% 61% 11% 
Fokouo, 2015 [37] Otoscopy, PTA  18% 62% 20% 
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Table 4: HIV characteristics and prevalence of hearing loss 
HIV 
characteristic 
Studies 
investigating 
Association with 
hearing loss 
Description Effect estimate 
ART  Chao [21]   Positive  Yes versus no OR=9.6, 1.2-75.4 
 Buriti [20] Positive Yes versus no OR=7.3 (1.3-41.4)* 
 Taipale [19] Null Yes versus no Not significant 
 Makau [29] Null Yes versus no P=0.12 
 Torre [26] Null Yes versus no  
 Fokou [37] Null Yes versus no Right ear: OR: 0.9 
(0.3-2.5)* 
Left ear: OR: 1.5 
(0.6-4.2)*  
 Maro [34] Null Yes versus no OR=2.5 (0.6-11.3)* 
 Maro [27] Null Yes versus no Not statistically 
significant 
 Matas[28] Null Yes versus no OR=2.4 (0.7-8.7)* 
     
CD4 count Chao [21] Positive  Low versus 
high: Cut-off: 
500 
OR=3.5, 1.2-10.5 
 Matsekete [25] Positive Low versus high: 
Cut-off <350 
P<0.02 
 Torre [26] Null   
 Ongulo [30] Positive Not stated “Found to be related” 
 Palacios [18] Null Mean CD4 count 0=0.08 
      
viral load Chao [21] Inverse High versus low: 
Cut-off: 400 
copies/mL 
OR=0.2 (0.1-0.6) 
 Buriti [20] Positive High versus low: 
Cut-off: 50 
copies/mL 
 
OR = 6.4 (0.9-46.1) 
 Torre [26] Null   
     
Opportunistic 
infections 
Buriti [20] Positive  P=0.003 
     
Stage of disease Westhuizen [33] Null CDC category P>0.05 
 Torre [26] Positive  OR=2.47 (1.0-5.9) 
 Ongulo [30] Positive  WHO clinical 
staging 
P=0,003 
 Mathews[36] Significant – 
direction not 
specified 
AIDS P=0.001 
 
* Calculated from figures in paper 
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Table 5: Quality of papers assessed in systematic review 
Quality variable Quality variable criteria Number 
of papers 
Percent 
Sampling Non probability 
Probability (+1) 
 
Not population based 
Population based (+1) 
 
21 
0 
 
21 
0 
100% 
0 
 
100% 
0 
Objectivity of HIV 
measurement 
Self-reported 
Clinical records/laboratory tests (+1) 
0 
21 
0 
100% 
Objectivity of 
hearing impairment 
measure 
Non-validated assessment tool 
Validated assessment tool, clinical 
evaluation (+1) 
1 
20 
5% 
95% 
Response rate Not reported or below 60% 
Reported and over 60% (+1) 
21 
0 
100% 
0 
Control for 
confounding 
No 
Yes (+1) 
N/A 
10 
1 
10 
48% 
5% 
48% 
 
 
Appendix: Search terms for Ovid database 
1.  ((Hearing or Acoustic or Ear*) adj5 (loss* or impair* or deficienc* or disable* or 
disabili* or handicap*)).sh,ti,ab. 
2.  (Deaf*).sh,ti,ab. 
3.  exp Hearing Loss/ or exp Deafness/  
4.  1 or 2 or 3  
5.  ((Developing or Low-income or low income or Middle-income or Middle-income or 
(Low and middle-income) or (Low- and middle-income) or Less-Developed or Less 
Developed or Least Developed or Under Developed or underdeveloped or Third-World) 
adj5 (countr* or nation* or world or econom*)).sh,ti,ab 
6.  exp Developing countries/ 
7.  (LIC or LICs or MIC or MICs or LMIC or LMICs or LAMIC or LAMICs or LAMI 
countr* or third world).sh,ti,ab 
8.  (Transitional countr* or Transitional econom* or Transition countr* or Transition 
econom*).sh,ti,ab 
9.  (Afghanistan or Albania or Algeria or American Samoa or Angola or Antigua or Barbuda 
or Argentina or Armenia or Azerbaijan or Bangladesh or Belarus or Byelarus or 
Byelorussia or Belorussia or Belize or Benin or Bhutan or Bolivia or Bosnia or 
Herzegovina or Hercegovina or Bosnia-Herzegovina or Bosnia-Hercegovina or Botswana 
or Brazil or Brasil or Bulgaria or Burkina or Upper Volta or Burundi or Urundi or 
Cambodia or Republic of Kampuchea or Cameroon or Cameroons or Cape Verde or 
Central African Republic or Chad or Chile or China or Colombia or Comoros or Comoro 
Islands or Comores or Congo or DRC or Zaire or Costa Rica or Cote d'Ivoire or Ivory 
Coast or Cuba or Djibouti or Obock or French Somaliland or Dominica or Dominican 
Republic or Ecuador or Egypt or United Arab Republic or El Salvador or Eritrea or 
Ethiopia or Fiji or Gabon or Gabonese Republic or Gambia or Georgia or Ghana or Gold 
Coast or Grenada or Guatemala or Guinea or Guinea-Bissau or Guiana or Guyana or Haiti 
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or Honduras or India or Indonesia or Iran or Iraq or Jamaica or Jordan or Kazakhstan or 
Kenya or Kiribati or Republic of Korea or North Korea or DPRK or Kosovo or 
Kyrgyzstan or Kirghizstan or Kirgizstan or Kirghizia or Kirgizia or Kyrgyz or Kirghiz or 
Kyrgyz Republic or Lao or Laos or Latvia or Lebanon or Lesotho or Basutoland or 
Liberia or Libya or Lithuania or Macedonia or Madagascar or Malagasy Republic or 
Malawi or Nyasaland or Malaysia or Malaya or Malay or Maldives or Mali or Marshall 
Islands or Mauritania or Mauritius or Mayotte or Mexico or Micronesia or Moldova or 
Moldovia or Mongolia or Montenegro or Morocco or Mozambique or Myanmar or 
Burma or Namibia or Nepal or Nicaragua or Niger or Nigeria or Pakistan or Palau or 
Palestine or Panama or Papua New Guinea or Paraguay or Peru or Philippines or 
Romania or Rumania or Roumania or Russia or Russian Federation or USSR or Soviet 
Union or Union of Soviet Socialist Republics or Rwanda or Ruanda-Urundi or Samoa or 
Samoan Islands or Sao Tome or Principe or Senegal or Serbia or Montenegro or 
Yugoslavia or Seychelles or Sierra Leone or Solomon Islands or Somalia or South Africa 
or Sri Lanka or Ceylon or Saint Kitts or St Kitts or Saint Christopher Island or Nevis or 
Saint Lucia or St Lucia or Saint Vincent or St Vincent or Grenadines or Sudan or 
Suriname or Surinam or Swaziland or Syria or Syrian Arab Republic or Tajikistan or 
Tadzhikistan or Tadjikistan or Tanzania or Thailand or Timor-Leste or East Timor or 
Togo or Togolese Republic or Tonga or Tunisia or Turkey or Turkmenistan or Turkmenia 
or Tuvalu or Uganda or Ukraine or Uruguay or Uzbekistan or Vanuatu or New Hebrides 
or Venezuela or Vietnam or Viet Nam or West Bank or Gaza or Yemen or Zambia or 
Zimbabwe or Rhodesia).sh,ti,ab 
10.  5 OR 6 OR 7 OR 8 OR 9 
11.  (HIV or Human Immunodeficiency Virus or Human Immun* deficiency 
Virus*).sh,ti,ab,cp. 
12.  (AIDS or Acquired Immunodeficiency Syndrome or Acquired Immun* Deficiency 
Syndrome).sh,ti,ab,cp. 
13.  Exp human immunodeficiency virus / or exp Acquired Immunodeficiency Syndrome/ 
14.  11 or 12 or 13 
15.  4 AND 10 AND 14 
 
 
 
 
